Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

Burtness, Barbara; Goldwasser, Meredith A.; Flood, William A.; Mattar, Bassam; Forastiere, Arlene A.

doi:10.1200/jco.2005.02.4646

Cited by 823 publications

(539 citation statements)

References 17 publications

Supporting

Mentioning

509

Contrasting

Unclassified

Order By: Relevance

“…97 Other regimens as cisplatin plus cetuximab improved response rate in a phase III trial but with no benefit of PFS which was the primary end-point. 98 Single agent activity remains poor but it may be an alternative when other options are exhausted. Classical drugs as methotrexate, cisplatin, 5-fluorouracil (5-FU) and bleomyin have shown responses of short duration (3-5 months) and 15-30% tumor reduction.…”

Section: Metastatic or Recurrent Disease (Stage Ivc)mentioning

confidence: 99%

“…56 In a phase III trial comparing cisplatin with or without the monoclonal antibody cetuximab for metastatic/ recurrent SCCHN patients, it was seen that doses of cetuximab may need to be adjusted for patients with very high levels of EGFR to achieve better response. 57 The EGFRvIII mutant variant has been found in up to 40% of SCCHN and it seems to contribute to cancer growth and resistance to EGFR targeting. EGFRvIII is seen in cells that overexpress wild-type EGFR suggesting that mutations are a later event caused by rapid proliferation induced by EGFR overexpression.…”

Section: Egfr/egfrviiimentioning

confidence: 99%

See 1 more Smart Citation

A genetic view of laryngeal cancer heterogeneity

2016

View full text Add to dashboard Cite

During the recent decades significant improvements in the understanding of laryngeal molecular biology allowed a better characterization of the tumor. However, despite increased molecular knowledge and clinical efforts, survival of patients with laryngeal cancer remains the same as 30 years ago. Although this result may not make major conclusions as preservation approaches were not broadly used until the time of database collection, it seems to be clear that there is still window for improvement.

show abstract

Section: Metastatic or Recurrent Disease (Stage Ivc)mentioning

confidence: 99%

Section: Egfr/egfrviiimentioning

confidence: 99%

A genetic view of laryngeal cancer heterogeneity

2016

View full text Add to dashboard Cite

show abstract

“…15,20 Randomized clinical trials have demonstrated that cetuximab not only possesses effective antitumor activity as a single agent, but also enhances the effects of radiation and various chemotherapy regimens. 15,17,[21][22][23] In this regard, immunohistochemical detection of EGFR expression may be used to identify eligible patients, although the degree of EGFR expression does not appear to correlate with the likelihood of tumor regression in response to cetuximab treatment. [24][25][26] Squamous cell carcinoma of the anal canal is an uncommon malignancy but its incidence has increased considerably in recent years among women and among men younger than 45 years.…”

mentioning

confidence: 99%

Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification

et al. 2006

View full text Add to dashboard Cite

Immunohistochemical detection of expression of the epidermal growth factor receptor (EGFR) has been utilized to identify eligible patients with solid malignant tumors, including colorectal adenocarcinoma, for monoclonal antibody therapy (eg, cetuximab). The EGFR status in squamous cell carcinoma of the anal canal, an uncommon malignancy traditionally treated with chemoradiation, has not been well investigated. In this study, 38 primary squamous cell carcinomas of the anal canal were immunohistochemically examined for EGFR expression and analyzed by fluorescence in situ hybridization (FISH) for EGFR gene copy numbers. The results showed a variable degree of EGFR expression in 21 (55%) tumors, among which 13 (62%) cases exhibited a 2 þ to 3 þ staining pattern according to the Dako EGFR phamDx interpretation guide. There were no significant differences among tumors stratified by stage, degree of keratinization, or tissue block storage times. FISH analysis showed that none of the 34 cases with interpretable results had EGFR gene amplification. Increased gene copy numbers due to polysomy 7 were seen in seven of 18 (39%) cases that expressed EGFR protein and four of 16 (25%) cases that did not (P ¼ 0.3876). Ten (56%) tumors with positive EGFR staining showed a balanced disomy 7 pattern and one case with monosomy 7 exhibited strong EGFR expression (3 þ ). These results demonstrate that EGFR is overexpressed in more than one-half of the squamous cell carcinomas of the anal canal through mechanisms other than gene amplification. These observations may have important therapeutic implications since EGFR-based targeted therapies have shown promise for other malignant neoplasms.

show abstract

“…Cetuximab also has demonstrated activity against recurrent and/or metastatic disease in the first-line setting when given in combination with cisplatin 23 and with cisplatin or carboplatin plus 5-fluororacil. 24,25 When initial platinum-based therapy has failed, encouraging results have been reported in patients with recurrent and/or metastatic SCCHN for cetuximab both as monotherapy 26,27 and in combination with either cisplatin or carboplatin.…”

mentioning

confidence: 99%

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

Vermorken

Herbst

León

et al. 2008

Cancer

185

118

View full text Add to dashboard Cite

A novel aryl‐bridged triphenylamine derivative, 7‐t‐butyl‐5,5,9,9‐tetraaryl‐13b‐aza‐naphtho[3,2,1‐de]anthracene (ABTPA) was designed and synthesized. The alternating copolymers of ABTPA/dihexylfluorene (P1) and triphenylamine (TPA)/dihexylfluorene (P2) were synthesized by Suzuki coupling reaction. P1 shows excellent thermal stability with a decomposition temperature of 440 °C and a glass‐transition temperature of 326 °C. The HOMO energy levels of the two polymers are very close (−5.15 eV for P1 and −5.13 eV for P2). The maximum absorption peak of P1 is red shifted by 23 nm with respect to P2, because the incorporation of ABTPA units into the PF backbone enhances the electronic conjugation degree compared with the case of TPA units. The rigidity and the steric hindrance of the ABTPA in P1 result in a small Stokes shift and almost the same emission spectra of P1 between its film and solution. A PLED with simple configurations of ITO/P1/TNS (tetranaphthalen‐2‐yl‐silane)/Alq3 (tris(8‐hydroxyquinolinolato)aluminum)/Al emits a blue light with emission peak at 436 nm, and exhibits a maximum current efficiency of 1.89 cd/A and a maximum luminance of 4183 cd/m2, which is superior to the device with P2 as emissive layer under the identical conditions. These results indicate that ABTPA unit could be a very promising candidate to replace TPA unit and find widely application in organic/polymeric optoelectronic materials. © 2009 Wiley Periodicals, Inc. J Polym Sci Part A: Polym Chem 47: 3651–3661, 2009

show abstract

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

Abstract: Addition of cetuximab to cisplatin significantly improves response rate. There was a survival advantage for the development of rash. Progression-free and overall survival were not significantly improved by the addition of cetuximab in this study.

Cited by 823 publications

References 17 publications

A genetic view of laryngeal cancer heterogeneity

A genetic view of laryngeal cancer heterogeneity

Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based therapies

Contact Info

Product

Resources

About